New Ray Medicine (06108) Sets 25 Mar 2026 Board Meeting to Approve FY 2025 Results and Final Dividend Proposal

Bulletin Express

Mar 12

New Ray Medicine International Holding Limited (06108) has scheduled a board meeting for 25 March 2026. The agenda includes approval of the audited financial results for the year ended 31 December 2025 and deliberation on a potential final dividend.

According to the announcement dated 12 March 2026, the meeting will be attended by the company’s executive directors—Wang Qiuqin (Chairman), Chu Xueping and Zhou Wan—and independent non-executive directors Leung Chi Kin, Li Sin Ming (Ivy) and Sy Lai Yin (Sunny).

No additional financial figures or dividend details were disclosed in the filing.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1155113008"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1155113008\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1155113008?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-12 20:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155113008","market":"us","top_or_hot":-1,"title":"New Ray Medicine (06108) Sets 25 Mar 2026 Board Meeting to Approve FY 2025 Results and Final Dividend Proposal","media":"Bulletin Express","content":"<p>New Ray Medicine International Holding Limited (06108) has scheduled a board meeting for 25 March 2026. The agenda includes approval of the audited financial results for the year ended 31 December 2025 and deliberation on a potential final dividend.</p>\n<p>According to the announcement dated 12 March 2026, the meeting will be attended by the company’s executive directors—Wang Qiuqin (Chairman), Chu Xueping and Zhou Wan—and independent non-executive directors Leung Chi Kin, Li Sin Ming (Ivy) and Sy Lai Yin (Sunny).</p>\n<p>No additional financial figures or dividend details were disclosed in the filing.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>New Ray Medicine (06108) Sets 25 Mar 2026 Board Meeting to Approve FY 2025 Results and Final Dividend Proposal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNew Ray Medicine (06108) Sets 25 Mar 2026 Board Meeting to Approve FY 2025 Results and Final Dividend Proposal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-12 20:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>New Ray Medicine International Holding Limited (06108) has scheduled a board meeting for 25 March 2026. The agenda includes approval of the audited financial results for the year ended 31 December 2025 and deliberation on a potential final dividend.</p>\n<p>According to the announcement dated 12 March 2026, the meeting will be attended by the company’s executive directors—Wang Qiuqin (Chairman), Chu Xueping and Zhou Wan—and independent non-executive directors Leung Chi Kin, Li Sin Ming (Ivy) and Sy Lai Yin (Sunny).</p>\n<p>No additional financial figures or dividend details were disclosed in the filing.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06108","symbol_name":"新锐医药","start_time":0,"source_url":"","article_id":"1155113008","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155113008","pubTimestamp":1773319356,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"New Ray Medicine International Holding Limited (06108) has scheduled a board meeting for 25 March 2026. The agenda includes approval of the audited financial results for the year ended 31 December...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06108":"新锐医药"},"translate_title":"新光医药(06108)定于2026年3月25日召开董事会批准2025财年业绩及末期股息建议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06108":1},"content_text":"New Ray Medicine International Holding Limited (06108) has scheduled a board meeting for 25 March 2026. The agenda includes approval of the audited financial results for the year ended 31 December 2025 and deliberation on a potential final dividend.\nAccording to the announcement dated 12 March 2026, the meeting will be attended by the company’s executive directors—Wang Qiuqin (Chairman), Chu Xueping and Zhou Wan—and independent non-executive directors Leung Chi Kin, Li Sin Ming (Ivy) and Sy Lai Yin (Sunny).\nNo additional financial figures or dividend details were disclosed in the filing.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}